Musculoskeletal conditions including osteoarthritis and chronic tendinopathies are leading causes of pain and disability worldwide. The emergence of novel regenerative therapies, referred to as orthobiologics, has led to promising interventions which may reduce pain and improve function. Orthobiologics are biological substances intended to enhance healing and alter the natural course of orthopaedic disease.1 2 Despite growing experience, the field remains under-researched with inconsistent evidence; yet increasing enthusiasm has permitted overexuberant, sometimes inappropriate use with proliferation of misinformation among both providers and patients. An American Medical Society for Sports Medicine (AMSSM) position statement was developed to help sports medicine physicians make informed and responsible decisions about the role of regenerative medicine in their practice.3 The statement contains relevant terminology, review of basic and clinical science, ethics, regulations and best practices for considering regenerative medicine in clinical practice (figure 1). The statement seeks to educate physicians regarding a broad and emerging discipline and is not an endorsement by AMSSM of any specific product or procedure. Figure 1 Responsible use of orthobiologics and other novel regenerative therapies requires multiple considerations before translation into routine clinical practice. Regenerative medicine is rapidly growing with terms and definitions yet to be standardised. While originating with stem cell discovery and translation, regenerative therapies, of which orthobiologics is but one category, are no longer a single platform technology. Rather, they now encompass a heterogeneous collection of biological sources with varying activity that hold the potential to transform human health. Common orthobiologics employed in research and clinical practice are being conflated under the umbrella of ‘stem cell’ therapy in a …

中文翻译：

---

美国运动医学医学会关于在运动医学中负责任地使用再生医学和骨科生物制剂的立场声明的要点

包括骨关节炎和慢性肌腱病在内的肌肉骨骼疾病是全世界疼痛和残疾的主要原因。新的再生疗法（称为骨生物制剂）的出现导致了有希望的干预措施，这些干预措施可以减轻疼痛并改善功能。骨科生物制剂是旨在促进愈合和改变骨科疾病自然病程的生物物质。1 2 尽管经验不断丰富，但该领域的研究仍然不足，证据不一致；然而，越来越多的热情已经允许过度使用，有时是不恰当的使用，错误信息在提供者和患者之间扩散。制定了美国运动医学医学会 (AMSSM) 立场声明，以帮助运动医学医师就再生医学在其实践中的作用做出知情和负责任的决定。3 该声明包含相关术语、基础和临床科学回顾、伦理学、在临床实践中考虑再生医学的法规和最佳实践（图 1）。该声明旨在对医生进行有关广泛和新兴学科的教育，而不是 AMSSM 对任何特定产品或程序的认可。图 1 在转化为常规临床实践之前，负责任地使用骨生物制剂和其他新型再生疗法需要多方面考虑。再生医学正在迅速发展，术语和定义尚未标准化。虽然起源于干细胞的发现和翻译，但骨生物制剂只是其中一个类别的再生疗法不再是单一的平台技术。相反，它们现在包含了具有不同活性的异质生物源集合，这些生物源具有改变人类健康的潜力。研究和临床实践中使用的常见骨生物制剂正在被归为“干细胞”治疗的保护伞……